It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site

March 2, 2016

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site

Otsuka Pharmaceutical's ABILIFY for Extended Release Injectable Suspension (chemical name is aripiprazole hydrate) in 300 mg and 400 mg vials and in 300 mg and 400 mg pre-filled syringes has received regulatory approval for administration at the deltoid muscle site in the upper arm.
ABILIFY long-acting injectable was introduced in Japan in May 2015 for the treatment of schizophrenia. Until now, the only administration site for the injectable form of the drug has been an intramuscular area of the buttocks.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases